Lundbeck banks on migraine therapy with $2bn acquisition 17-Sep-2019 By Ben Hargreaves Lundbeck agrees to purchase Alder to gain access to its CGRP migraine therapy that looks set to enter a crowded market.
Lilly aims to leapfrog rivals with cluster headache approval 05-Jun-2019 By Ben Hargreaves US FDA approves Eli Lilly’s Emgality for episodic cluster headaches, putting it ahead of its rivals in the CGRP space.
Teva highlights quarterly dosing of migraine med as EU gives positive opinion 07-Feb-2019 By Ben Hargreaves After a CHMP positive opinion, Teva’s Ajovy looks set to receive final approval to enter the EU market in the coming months.
